What HOOKIPA Pharma Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 0 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Peters Malte | Chief Executive Officer | Aug 19 | Open-market sale · S | −25,172 | $0.82 | −$20.7K | 54,347 |
| Peters Malte | Chief Executive Officer | Jul 22 | Open-market sale · S | −29,176 | $0.92 | −$26.8K | 79,519 |
| Coelho Mary Theresa | EVP and CFO | Jul 22 | Open-market sale · S | −13,609 | $0.92 | −$12.5K | 56,266 |
| Peters Malte | Chief Executive Officer | Jul 22 | Grant / award · A | +108,695 | — | — | 108,695 |
| Coelho Mary Theresa | EVP and CFO | Jul 22 | Grant / award · A | +69,875 | — | — | 69,875 |
| Kandera Reinhard | Chief Financial Officer | Aug 21 | Open-market buy · P | +7,000 | $0.73 | +$5.08K | 43,092 |
| Kandera Reinhard | Chief Financial Officer | Aug 16 | Open-market buy · P | +8,000 | $0.71 | +$5.71K | 36,092 |
| Aldag Jorn | Chief Executive Officer | Jul 11 | Open-market buy · P | +5,000 | $0.83 | +$4.14K | 71,952 |
| Aldag Jorn | Chief Executive Officer | Jul 07 | Open-market buy · P | +5,000 | $0.81 | +$4.05K | 66,952 |
| Aldag Jorn | Chief Executive Officer | Jul 05 | Open-market buy · P | +5,000 | $0.89 | +$4.45K | 61,952 |
| Aldag Jorn | Chief Executive Officer | Jul 03 | Open-market buy · P | +5,000 | $0.89 | +$4.46K | 56,952 |
| Kandera Reinhard | Chief Financial Officer | Jun 30 | Open-market buy · P | +12,000 | $0.88 | +$10.6K | 28,092 |
| Kandera Reinhard | Chief Financial Officer | Feb 01 | Grant / award · A | +14,056 | $3.00 | +$42.2K | 16,092 |
| Aldag Jorn | Chief Executive Officer | Feb 01 | Grant / award · A | +47,824 | $3.00 | +$143K | 51,952 |
| Matushansky Igor | Chief Medical Officer | Feb 01 | Grant / award · A | +14,933 | $3.00 | +$44.8K | 100,240 |
| Necina Roman | Chief Technology Officer | Feb 01 | Grant / award · A | +12,892 | $3.00 | +$38.7K | 14,876 |
| Baker Christine D. | Chief Business Officer | Feb 01 | Grant / award · A | +13,658 | $3.00 | +$41K | 16,158 |
| Orlinger Klaus | Executive VP, Research | Feb 01 | Grant / award · A | +9,188 | $3.00 | +$27.6K | 10,404 |
| Matushansky Igor | Chief Medical Officer | Dec 21 | Open-market sale · S | −2,205 | $2.49 | −$5.49K | 85,307 |
| Matushansky Igor | Chief Medical Officer | Dec 21 | Exercise / conversion · M | +3,408 | $0.10 | +$341 | 87,512 |
Loading...
